Westpark Capital reaffirmed their outperform rating on shares of Biocept (NASDAQ:BIOC) in a research report sent to investors on Wednesday morning. They currently have a $1.00 target price on the medical research company’s stock.
Separately, Zacks Investment Research raised shares of Biocept from a hold rating to a buy rating and set a $0.75 target price on the stock in a report on Monday, January 15th.
BIOC stock opened at $0.27 on Wednesday. Biocept has a one year low of $0.23 and a one year high of $1.98. The company has a current ratio of 0.91, a quick ratio of 0.81 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $17.95, a PE ratio of -0.34 and a beta of 1.77.
Biocept (NASDAQ:BIOC) last released its earnings results on Wednesday, March 28th. The medical research company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.02). Biocept had a negative return on equity of 374.92% and a negative net margin of 426.48%. The company had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $1.23 million. equities research analysts predict that Biocept will post -0.44 EPS for the current year.
A hedge fund recently raised its stake in Biocept stock. Vanguard Group Inc. boosted its holdings in shares of Biocept Inc (NASDAQ:BIOC) by 9.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 764,351 shares of the medical research company’s stock after purchasing an additional 66,746 shares during the quarter. Vanguard Group Inc. owned about 2.87% of Biocept worth $1,048,000 as of its most recent SEC filing. 9.29% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Biocept (BIOC) Given “Outperform” Rating at Westpark Capital” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/biocept-bioc-given-outperform-rating-at-westpark-capital.html.
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.